反応式
[F:1][C:2]([F:13])([F:12])[C:3]1[CH:8]=[CH:7][C:6]([C:9](Cl)=[O:10])=[CH:5][CH:4]=1.[NH2:14][C:15]1[CH:20]=[CH:19][C:18]([C:21]2[C:29]3[C:24](=[N:25][CH:26]=[N:27][C:28]=3[NH2:30])[N:23]([CH:31]3[CH2:36][CH2:35][N:34]([CH:37]4CCN(C)CC4)[CH2:33][CH2:32]3)[N:22]=2)=[CH:17][C:16]=1[O:44][CH3:45]>N1C=CC=CC=1>[NH2:30][C:28]1[N:27]=[CH:26][N:25]=[C:24]2[N:23]([CH:31]3[CH2:36][CH2:35][N:34]([CH3:37])[CH2:33][CH2:32]3)[N:22]=[C:21]([C:18]3[CH:19]=[CH:20][C:15]([NH:14][C:9](=[O:10])[C:6]4[CH:7]=[CH:8][C:3]([C:2]([F:13])([F:12])[F:1])=[CH:4][CH:5]=4)=[C:16]([O:44][CH3:45])[CH:17]=3)[C:29]=12参加物
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
4-(Trifluoromethyl)-1-benzenecarbonyl chloride (48 mg, 0.231 mmol) was added to a solution of 3-(4-amino-3-methoxyphenyl)-1-[1-(1-methylpiperidin-4-yl)-piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine (101 mg, 0.231 mmol) in pyridine (1.0 mL). After 5 hours, the solvent was evaporated and the residue was purified by flash column chromatography to give N1-{4-[4-amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl}-4-(trifluoromethyl)benzamide (83 mg, 59%). 1H NMR (CDCl3-d) δ 1.68 (m, 2H), 1.82 (m, 4H), 2.01 (m, 4H), 2.29 (s, 3H), 2.44 (m, 3H), 2.93 (m, 2H), 3.30 (m, 2H), 4.03 (s, 3H), 4.77 (m, 1H), 5.60 s, 2H), 7.33 (m, 2H), 1.79 d, J=8.19 Hz, 2H), 8.04 (d, J=8.04 Hz, 2H), 8.37 (s, 1H), 8.66 (m, 2H). LCMS (Micromass-Column: Pecosphere, C18, 3 um, 33×4.6 mm. Eluents: 0% B/A to 100% B/A in 4.5 min.(B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5), 3.5 mL/min.): MH+ =609.4, Rt=2.50 min.
後処理
- customthe solvent was evaporated
- customthe residue was purified by flash column chromatography
出典と根拠
- ORDレコード
- ord-2ddcbf2b35464074a2319289871f58ca
- 出典データセット
- uspto-grants-2003_12
- 特許番号
- US06660744B1
関連ノート
読み込み中…